+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
CURIS

Curis Lifesciences Share Price

 

 

Curis Lifesciences live price: ₹110. It opened at ₹112 vs previous close ₹112; intraday high/low: ₹112/₹110. The 50 DMA stands at ₹114.89.

Curis Lifesciences Performance

  • Today's Low
  • ₹110
  • Today's High
  • ₹112
  • 52 Week Low
  • ₹84
  • 52 Week High
  • ₹148
  • Open Price₹112
  • Previous Close₹112
  • Volume3,000
  • 50 DMA₹114.89
  • 100 DMA₹115.60
  • 200 DMA-

Curis Lifesciences Chart

Investment Returns

  • Over 1 Month -17.6%
  • Over 3 Month + 18.09%
  • Over 6 Month -1.79%
  • Over 1 Year -14.06%

Smart Investing Starts Here Start SIP with Curis Lifesciences for Steady Growth!

Invest Now

Curis Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 12.9
  • PEG Ratio
  • -
  • Market Cap Cr
  • 89
  • P/B Ratio
  • 1.9
  • Average True Range
  • 3.82
  • EPS
  • 8.57
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.91
  • RSI
  • 40.17
  • MFI
  • 23.93

Latest Stock News Updates

Curis Lifesciences Acquires Majority Stake in Uninova, Accelerates Multi-Continent Expansion

.

Curis Lifesciences Financials

Curis Lifesciences Technicals

EMA & SMA

Current Price
₹110.00
-1.95 (-1.74%)
pointer
  • Bearish Moving Average 13
  • Bullish Moving Average 0
  • 20 Day
  • ₹115.50
  • 50 Day
  • ₹114.90
  • 100 Day
  • ₹115.60
  • 200 Day
  • -

Resistance and Support

110.65 Pivot Speed
  • R3 113.25
  • R2 112.60
  • R1 111.30
  • S1 109.35
  • S2 108.70
  • S3 107.40

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Curis Lifesciences manufactures pharmaceutical products with a specialization in ophthalmic sterile ointments. The company focuses on producing high-quality, compliant formulations for healthcare needs, supported by dedicated manufacturing capabilities and a growing presence in the domestic pharmaceutical market.

Curis Lifesciences Ltd has an operating revenue of Rs. 145.32 Cr. on a trailing 12-month basis. An annual revenue growth of 23% is outstanding, Pre-tax margin of 16% is great, ROE of 14% is good. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -16% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 78 which is a FAIR score but needs to improve its earnings, a RS Rating of 56 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Ethical Drugs and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Curis Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-30 Audited Results
2025-12-04 Quarterly Results

Curis Lifesciences Shareholding Pattern

68.03%
0%
1.19%
0.06%
14.38%
16.34%

Curis Lifesciences FAQs

Curis Lifesciences share price is ₹110 As on 15 June, 2026 | 19:05

The Market Cap of Curis Lifesciences is ₹88.9 Cr As on 15 June, 2026 | 19:05

The P/E ratio of Curis Lifesciences is 12.9 As on 15 June, 2026 | 19:05

The PB ratio of Curis Lifesciences is 1.9 As on 15 June, 2026 | 19:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23